Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

idecabtagene vicleucel

(I-deh-KAB-tuh-jeen vik-LOO-sel)
A treatment used for adults with multiple myeloma that came back or did not get better after treatment with at least two lines of anticancer therapy that included an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Idecabtagene vicleucel is made using a patient’s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Idecabtagene vicleucel binds to a protein called BCMA, which is found on myeloma cells and some types of immune cells. This helps the body’s immune system kill cancer cells. Idecabtagene vicleucel is a type of cellular immunotherapy called CAR T-cell therapy. Also called Abecma.
More Information
Search NCI's Dictionary of Cancer Terms